Physician profile
Thor Agustsson
NPI 1427219948
$3,295.27
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,729 · 2020: $795 · 2021: $679 · 2022: $91.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $968.71 | 2019-2020 | |
| Abbvie INC. | $471.59 | 2021 | |
| Neos Therapeutics, LP | $467.27 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $328.07 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $309.35 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $224.55 | 2019-2021 | |
| Lundbeck LLC | $109.76 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $93.78 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $65.45 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $50.60 | 2019-2020 | |
| Shire North American Group INC | $49.13 | 2019 | |
| Ironshore Pharmaceuticals INC. | $38.24 | 2019 | |
| Neurocrine Biosciences, INC. | $37.07 | 2019 | |
| Merck Sharp & Dohme LLC | $26.41 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.43 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $13.80 | 2020 | |
| Rhodes Pharmaceuticals L.P. | $13.50 | 2019 | |
| Alfasigma USA, INC. | $11.56 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thor Agustsson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.